Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

DRUG

BMS-690514

Tablets, Oral, 200 mg, once daily, until disease progression or toxicity

Trial Locations (4)

Local Institution, Koto-Ku

Local Institution, Kashiwa-Shi

Local Institution, Sunto-Gun

Local Institution, Osaka-Sayama-Shi